ESC 2025 29 August - 1 September 2025

Effects of oral semaglutide on heart failure outcomes in people with type 2 diabetes and atherosclerotic cardiovascular disease and/or chronic kidney disease participating in SOUL trial

Sorry! It looks like the page you are trying to access contains materials that are still under embargo. Please come back and check again later.
Keywords
Diabetes
Congress oral presentation
GLP-1 RA
Semaglutide (oral)
PHASE 3 (RCT)